Table of Contents Author Guidelines Submit a Manuscript
Neural Plasticity
Volume 2012, Article ID 171639, 14 pages
http://dx.doi.org/10.1155/2012/171639
Review Article

Molecular and Cellular Alterations in Down Syndrome: Toward the Identification of Targets for Therapeutics

Unité de Biologie Fonctionnelle et Adaptative (BFA), Sorbonne Paris Cité, Universite Paris Diderot, EAC4413 CNRS, 75205 Paris Cedex 13, France

Received 3 February 2012; Revised 18 April 2012; Accepted 19 April 2012

Academic Editor: Hansen Wang

Copyright © 2012 Nicole Créau. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. F. Pennington, J. Moon, J. Edgin, J. Stedron, and L. Nadel, “The neuropsychology of Down Syndrome: evidence for hippocampal dysfunction,” Child Development, vol. 74, no. 1, pp. 75–93, 2003. View at Google Scholar · View at Scopus
  2. J. B. Leverenz and M. A. Raskind, “Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis,” Experimental Neurology, vol. 150, no. 2, pp. 296–304, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Nistor, M. Don, M. Parekh et al., “Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain,” Neurobiology of Aging, vol. 28, no. 10, pp. 1493–1506, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Hanney, V. Prasher, N. Williams et al., “Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 379, no. 9815, pp. 528–536, 2012. View at Google Scholar
  5. J. O. Edgin, G. M. Mason, M. J. Allman et al., “Development and validation of the Arizona Cognitive Test Battery for Down syndrome,” Journal of Neurodevelopmental Disorders, vol. 2, no. 3, pp. 149–164, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. F. A. Conners, M. S. Moore, S. J. Loveall, and E. C. Merrill, “Memory profiles of Down, Williams, and fragile X syndromes: implications for reading development,” Journal of Developmental & Behavioral Pediatrics, vol. 32, no. 5, pp. 405–417, 2011. View at Publisher · View at Google Scholar
  7. K. A. B. Næss, S. A. H. Lyster, C. Hulme, and M. Melby-Lervåg, “Language and verbal short-term memory skills in children with Down syndrome: a meta-analytic review,” Research in Developmental Disabilities, vol. 32, no. 6, pp. 2225–2234, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Lanfranchi, A. Baddeley, S. Gathercole, and R. Vianello, “Working memory in Down syndrome: is there a dual task deficit?” Journal of Intellectual Disability Research, vol. 56, no. 2, pp. 157–166, 2012. View at Publisher · View at Google Scholar
  9. E. H. Aylward, Q. Li, N. A. Honeycutt et al., “MRI volumes of the hippocampus and amygdala in adults with Down's syndrome with and without dementia,” American Journal of Psychiatry, vol. 156, no. 4, pp. 564–568, 1999. View at Google Scholar · View at Scopus
  10. J. D. Pinter, S. Eliez, J. E. Schmitt, G. T. Capone, and A. L. Reiss, “Neuroanatomy of Down's syndrome: a high-resolution MRI study,” American Journal of Psychiatry, vol. 158, no. 10, pp. 1659–1665, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Rigoldi, M. Galli, C. Condoluci, F. Carducci, P. Onorati, and G. Albertini, “Gait analysis and cerebral volumes in Down's syndrome,” Functional Neurology, vol. 24, no. 3, pp. 147–152, 2009. View at Google Scholar · View at Scopus
  12. D. Menghini, F. Costanzo, and S. Vicari, “Relationship between brain and cognitive processes in down syndrome,” Behavior Genetics, vol. 41, no. 3, pp. 381–393, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Brunamonti, P. Pani, O. Papazachariadis, P. Onorati, G. Albertini, and S. Ferraina, “Cognitive control of movement in down syndrome,” Research in Developmental Disabilities, vol. 32, no. 5, pp. 1792–1797, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Lejeune, M. Gautier, and R. Turpin, “Study of somatic chromosomes from 9 mongoloid children,” Comptes Rendus Hebdomadaires des Séances de l'Académie des Sciences, vol. 248, no. 11, pp. 1721–1722, 1959. View at Google Scholar · View at Scopus
  15. E. Aït Yahya-Graison, J. Aubert, L. Dauphinot et al., “Classification of human chromosome 21 gene-expression variations in down syndrome: impact on disease phenotypes,” American Journal of Human Genetics, vol. 81, no. 3, pp. 475–491, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Prandini, S. Deutsch, R. Lyle et al., “Natural gene-expression variation in Down syndrome modulates the outcome of gene-dosage imbalance,” American Journal of Human Genetics, vol. 81, no. 2, pp. 252–263, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Kahlem, M. Sultan, R. Herwig et al., “Transcript level alterations reflect gene dosage effects across multiple tissues in a mouse model of Down syndrome,” Genome Research, vol. 14, no. 7, pp. 1258–1267, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Lyle, C. Gehrig, C. Neergaard-Henrichsen, S. Deutsch, and S. E. Antonarakis, “Gene expression from the aneuploid chromosome in a trisomy mouse model of Down syndrome,” Genome Research, vol. 14, no. 7, pp. 1268–1274, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Mao, X. Wang, E. L. Spitznagel et al., “Primary and secondary transcriptional effects in the developing human Down syndrome brain and heart,” Genome Biology, vol. 6, no. 13, article R107, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. H. E. Lockstone, L. W. Harris, J. E. Swatton, M. T. Wayland, A. J. Holland, and S. Bahn, “Gene expression profiling in the adult Down syndrome brain,” Genomics, vol. 90, no. 6, pp. 647–660, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. J. H. K. Choi, J. D. Berger, M. J. Mazzella et al., “Age-dependent dysregulation of brain amyloid precursor protein in the Ts65Dn Down syndrome mouse model,” Journal of Neurochemistry, vol. 110, no. 6, pp. 1818–1827, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. M. T. Davisson, C. Schmidt, and E. C. Akeson, “Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome,” Progress in Clinical and Biological Research, vol. 360, pp. 263–280, 1990. View at Google Scholar · View at Scopus
  23. H. Sago, E. J. Carlson, D. J. Smith et al., “Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 11, pp. 6256–6261, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. K. J. Ahn, H. K. Jeong, H. S. Choi et al., “DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects,” Neurobiology of Disease, vol. 22, no. 3, pp. 463–472, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Guedj, P. L. Pereira, S. Najas et al., “DYRK1A: a master regulatory protein controlling brain growth,” Neurobiology of Disease, vol. 46, no. 1, pp. 190–203, 2012. View at Publisher · View at Google Scholar
  26. J. Laffaire, I. Rivals, L. Dauphinot et al., “Gene expression signature of cerebellar hypoplasia in a mouse model of Down syndrome during postnatal development,” BMC Genomics, vol. 10, article 138, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Duchon, M. Raveau, C. Chevalier, V. Nalesso, A. J. Sharp, and Y. Herault, “Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling down syndrome,” Mammalian Genome, vol. 22, no. 11-12, pp. 674–684, 2011. View at Publisher · View at Google Scholar
  28. L. G. Reinholdt, Y. Ding, G. T. Gilbert et al., “Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn,” Mammalian Genome, vol. 22, no. 11-12, pp. 685–691, 2011. View at Publisher · View at Google Scholar
  29. Z. Li, T. Yu, M. Morishima et al., “Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities,” Human Molecular Genetics, vol. 16, no. 11, pp. 1359–1366, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. P. L. Pereira, L. Magnol, I. Sahún et al., “A new mouse model for the trisomy of the Abcg1-U2af1 region reveals the complexity of the combinatorial genetic code of down syndrome,” Human Molecular Genetics, vol. 18, no. 24, pp. 4756–4769, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Yu, Z. Li, Z. Jia et al., “A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions,” Human Molecular Genetics, vol. 19, no. 14, pp. 2780–2791, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. A. O'Doherty, S. Ruf, C. Mulligan et al., “Genetics: an aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes,” Science, vol. 309, no. 5743, pp. 2033–2037, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. B. T. Lamb, S. S. Sisodia, A. M. Lawler et al., “Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice,” Nature Genetics, vol. 5, pp. 22–30, 1993. View at Google Scholar
  34. D. J. Smith and E. M. Rubin, “Functional screening and complex traits: human 21q22.2 sequences affecting learning in mice,” Human Molecular Genetics, vol. 6, no. 10, pp. 1729–1733, 1997. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Morice, L. C. Andreae, S. F. Cooke et al., “Preservation of long-term memory and synaptic plasticity despite short-term impairments in the Tcl mouse model of down syndrome,” Learning and Memory, vol. 15, no. 7, pp. 492–500, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. P. Papavassiliou, T. P. York, N. Gursoy et al., “The phenotype of persons having mosaicism for trisomy 21/down syndrome reflects the percentage of trisomic cells present in different tissues,” American Journal of Medical Genetics, Part A, vol. 149, no. 4, pp. 573–583, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. A. M. Lepagnol-Bestel, A. Zvara, G. Maussion et al., “DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome,” Human Molecular Genetics, vol. 18, no. 8, pp. 1405–1414, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. F. Mouton-Liger, S. Thomas, R. Rattenbach et al., “PCP4 (PEP19) overexpression induces premature neuronal differentiation associated with Ca2+/Calmodulin-Dependent kinase II-δ activation in mouse models of down syndrome,” Journal of Comparative Neurology, vol. 519, no. 14, pp. 2779–2802, 2011, Erratum in: Journal of Comparative Neurology, vol.519 no. 17, p. 3597, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Amano, H. Sago, C. Uchikawa et al., “Dosage-dependent over-expression of genes in the trisomic region of Ts1 Cje mouse model for Down syndrome,” Human Molecular Genetics, vol. 13, no. 13, pp. 1333–1340, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. N. Sahir, D. E. Brenneman, and J. M. Hill, “Neonatal mice of the Down syndrome model, Ts65Dn, exhibit upregulated VIP measures and reduced responsiveness of cortical astrocytes to VIP stimulation,” Journal of Molecular Neuroscience, vol. 30, no. 3, pp. 329–340, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Harashima, D. M. Jacobowitz, M. Stoffel et al., “Elevated expression of the G-protein-activated inwardly rectifying potassium channel 2 (GIRK2) in cerebellar unipolar brush cells of a Down syndrome mouse model,” Cellular and Molecular Neurobiology, vol. 26, no. 4-6, pp. 719–734, 2006. View at Google Scholar · View at Scopus
  42. F. Guedj, C. Sébrié, I. Rivals et al., “Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A,” PLoS ONE, vol. 4, no. 2, article e4606, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Braudeau, L. Dauphinot, A. Duchon et al., “Chronic treatment with a promnesiant GABA-A α5 -selective inverse agonist increases immediate early genes expression during memory processing in mice and rectifies their expression levels in a Down syndrome mouse model,” Advances in Pharmacological Sciences, vol. 2011, Article ID 153218, 11 pages, 2011. View at Publisher · View at Google Scholar
  44. N. G. Saran, M. T. Pletcher, J. E. Natale, Y. Cheng, and R. H. Reeves, “Global disruption of the cerebellar transcriptome in a Down syndrome mouse model,” Human Molecular Genetics, vol. 12, no. 16, pp. 2013–2019, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. D. M. Holtzman, D. Santucci, J. Kilbridge et al., “Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 23, pp. 13333–13338, 1996. View at Publisher · View at Google Scholar · View at Scopus
  46. D. E. Kuhn, G. J. Nuovo, M. M. Martin et al., “Human chromosome 21-derived miRNAs are overexpressed in down syndrome brains and hearts,” Biochemical and Biophysical Research Communications, vol. 370, no. 3, pp. 473–477, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Toso, I. Cameroni, R. Roberson, D. Abebe, S. Bissell, and C. Y. Spong, “Prevention of developmental delays in a down syndrome mouse model,” Obstetrics and Gynecology, vol. 112, no. 6, pp. 1242–1251, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. J. M. Hill, A. M. Ades, S. K. McCune et al., “Vasoactive intestinal peptide in the brain of a mouse model for Down syndrome,” Experimental Neurology, vol. 183, no. 1, pp. 56–65, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Lockrow, H. Boger, H. Bimonte-Nelson, and A. C. Granholm, “Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome,” Behavioural Brain Research, vol. 221, no. 2, pp. 610–622, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. S. D. Ginsberg, M. J. Alldred, and S. Che, “Gene expression levels assessed by CA1 pyramidal neuron and regional hippocampal dissections in Alzheimer's disease,” Neurobiology of Disease, vol. 45, no. 1, pp. 99–107, 2012. View at Publisher · View at Google Scholar
  51. A. Salehi, J. D. Delcroix, P. V. Belichenko et al., “Increased App Expression in a Mouse Model of Down's Syndrome Disrupts NGF Transport and Causes Cholinergic Neuron Degeneration,” Neuron, vol. 51, no. 1, pp. 29–42, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Siddiqui, T. Lacroix, M. R. Stasko, J. J. Scott-McKean, A. C. S. Costa, and K. J. Gardiner, “Molecular responses of the Ts65Dn and Ts1Cje mouse models of Down syndrome to MK-801,” Genes, Brain and Behavior, vol. 7, no. 7, pp. 810–820, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. R. M. Escorihuela, I. F. Vallina, C. Martínez-Cué et al., “Impaired short- and long-term memory in Ts65Dn mice, a model for Down syndrome,” Neuroscience Letters, vol. 247, no. 2-3, pp. 171–174, 1998. View at Publisher · View at Google Scholar · View at Scopus
  54. S. V. Voronov, S. G. Frere, S. Giovedi et al., “Synaptojanin 1-linked phosphoinositide dyshomeostasis and cognitive deficits in mouse models of Down's syndrome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 27, pp. 9415–9420, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. M. P. Hunter, M. Nelson, M. Kurzer et al., “Intersectin 1 contributes to phenotypes in vivo: implications for Down's syndrome,” NeuroReport, vol. 22, no. 15, pp. 767–772, 2011. View at Publisher · View at Google Scholar
  56. G. Ermak, M. A. Pritchard, S. Dronjak, B. Niu, and K. J. A. Davies, “Do RCAN1 proteins link chronic stress with neurodegeneration?” FASEB Journal, vol. 25, no. 10, pp. 3306–3311, 2011. View at Publisher · View at Google Scholar
  57. V. Régnier, J.-M. Billard, S. Gupta et al., “Brain phenotype of transgenic mice overexpressing cystathionine β-synthase,” PLoS ONE, vol. 7, no. 1, Article ID e29056, 2012. View at Publisher · View at Google Scholar
  58. K. Aldridge, R. H. Reeves, L. E. Olson, and J. T. Richtsmeier, “Differential effects of trisomy on brain shape and volume in related aneuploid mouse models,” American Journal of Medical Genetics, Part A, vol. 143, no. 10, pp. 1060–1070, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. M. M. de Lagrán, R. Benavides-Piccione, I. Ballesteros-Yañez et al., “Dyrk1A influences neuronal morphogenesis through regulation of cytoskeletal dynamics in mammalian cortical neurons,” Cerebral Cortex. In press.
  60. M. Álvarez, X. Estivill, and S. de la Luna, “DYRK1A accumulates in splicing speckles through a novel targeting signal and induces speckle disassembly,” Journal of Cell Science, vol. 116, no. 15, pp. 3099–3107, 2003. View at Publisher · View at Google Scholar · View at Scopus
  61. J. Shi, T. Zhang, C. Zhou et al., “Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in down syndrome,” Journal of Biological Chemistry, vol. 283, no. 42, pp. 28660–28669, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. D. Toiber, G. Azkona, S. Ben-Ari, N. Torán, H. Soreq, and M. Dierssen, “Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations,” Neurobiology of Disease, vol. 40, no. 1, pp. 348–359, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Wegiel, C. X. Gong, and Y. W. Hwang, “The role of DYRK1A in neurodegenerative diseases,” FEBS Journal, vol. 278, no. 2, pp. 236–245, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. I. Ferrer, M. Barrachina, B. Puig et al., “Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models,” Neurobiology of Disease, vol. 20, no. 2, pp. 392–400, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. O. Sheppard, F. Plattner, A. Rubin et al., “Altered regulation of tau phosphorylation in a mouse model of down syndrome aging,” Neurobiology of Aging, vol. 33, no. 4, pp. 828.e31–828.e44, 2012. View at Publisher · View at Google Scholar
  66. S. Bian and T. Sun, “Functions of noncoding RNAs in neural development and neurological diseases,” Molecular Neurobiology, vol. 44, no. 3, pp. 359–373, 2011. View at Google Scholar
  67. T. S. Elton, S. E. Sansom, and M. M. Martin, “Trisomy-21 gene dosage overexpression of miRNAs results in the haploinsufficiency of specific target proteins,” RNA Biology, vol. 7, no. 5, pp. 540–547, 2010. View at Google Scholar · View at Scopus
  68. Y. Y. Li, P. N. Alexandrov, A. I. Pogue, Y. Zhao, S. Bhattacharjee, and W. J. Lukiw, “miRNA-155 upregulation and complement factor H deficits in Down's syndrome,” Neuroreport, vol. 23, no. 3, pp. 168–173, 2012. View at Google Scholar
  69. D. E. Kuhn, G. J. Nuovo, A. V. Terry et al., “Chromosome 21-derived microRNAs provide an etiological basis for aberrant protein expression in human down syndrome brains,” Journal of Biological Chemistry, vol. 285, no. 2, pp. 1529–1543, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. A. I. Pogue, J. G. Cui, Y. Y. Li, Y. Zhao, F. Culicchia, and W. J. Lukiw, “Micro RNA-125b (miRNA-125b) function in astrogliosis and glial cell proliferation,” Neuroscience Letters, vol. 476, no. 1, pp. 18–22, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. G. Pollonini, V. Gao, A. Rabe, S. Palminiello, G. Albertini, and C. M. Alberini, “Abnormal expression of synaptic proteins and neurotrophin-3 in the down syndrome mouse model Ts65Dn,” Neuroscience, vol. 156, no. 1, pp. 99–106, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Trazzi, V. M. Mitrugno, E. Valli et al., “APP-dependent up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome,” Human Molecular Genetics, vol. 20, no. 8, pp. 1560–1573, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. T. K. Best, N. P. Cramer, L. Chakrabarti, T. F. Haydar, and Z. Galdzicki, “Dysfunctional hippocampal inhibition in the Ts65Dn mouse model of Down syndrome,” Experimental Neurology, vol. 233, no. 2, pp. 749–757, 2012. View at Publisher · View at Google Scholar
  74. M. A. Cortez, L. Shen, Y. Wu et al., “Infantile spasms and Down syndrome: a new animal model,” Pediatric Research, vol. 65, no. 5, pp. 499–503, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. P. Bianchi, E. Ciani, S. Guidi et al., “Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for down syndrome,” Journal of Neuroscience, vol. 30, no. 26, pp. 8769–8779, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. R. Roberson, L. Toso, D. Abebe, and C. Y. Spong, “Altered expression of KIF17, a kinesin motor protein associated with NR2B trafficking, may mediate learning deficits in a Down syndrome mouse model,” American Journal of Obstetrics and Gynecology, vol. 198, no. 3, pp. 313.e1–313.e4, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. R. J. Siarey, A. Kline-Burgess, M. Cho et al., “Altered signaling pathways underlying abnormal hippocampal synaptic plasticity in the Ts65Dn mouse model of Down syndrome,” Journal of Neurochemistry, vol. 98, no. 4, pp. 1266–1277, 2006, Erratum in: Journal of Neurochemistry, vol. 99, no. 4. p. 1320, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. H. Seo and O. Isacson, “Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice,” Experimental Neurology, vol. 193, no. 2, pp. 469–480, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Gotti, S. Chiavegatto, M. Sica, C. Viglietti-Panzica, R. J. Nelson, and G. Panzica, “Alteration of NO-producing system in the basal forebrain and hypothalamus of Ts65Dn mice: an immunohistochemical and histochemical study of a murine model for Down syndrome,” Neurobiology of Disease, vol. 16, no. 3, pp. 563–571, 2004. View at Publisher · View at Google Scholar · View at Scopus
  80. D. Pérez-Cremades, S. Hernández, J. M. Blasco-Ibáñez, C. Crespo, J. Nacher, and E. Varea, “Alteration of inhibitory circuits in the somatosensory cortex of Ts65Dn mice, a model for Down's syndrome,” Journal of Neural Transmission, vol. 117, no. 4, pp. 445–455, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Millan Sanchez, S. N. Heyn, D. Das, S. Moghadam, K. J. Martin, and A. Salehi, “Neurobiological elements of cognitive dysfunction in down syndrome: exploring the role of APP,” Biological Psychiatry, vol. 71, no. 5, pp. 403–409, 2012. View at Publisher · View at Google Scholar
  82. C. L. Hunter, D. Bachman, and A. C. Granholm, “Minocycline prevents cholinergic loss in a mouse model of Down's syndrome,” Annals of Neurology, vol. 56, no. 5, pp. 675–688, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. A. Contestabile, T. Fila, R. Bartesaghi, A. Contestabile, and E. Ciani, “Choline acetyltransferase activity at different ages in brain of Ts65Dn mice, an animal model for Down's syndrome and related neurodegenerative diseases,” Journal of Neurochemistry, vol. 97, no. 2, pp. 515–526, 2006. View at Publisher · View at Google Scholar · View at Scopus
  84. J. D. Cooper, A. Salehi, J. D. Delcroix et al., “Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 18, pp. 10439–10444, 2001. View at Publisher · View at Google Scholar · View at Scopus
  85. D. Necchi, S. Lomoio, and E. Scherini, “Axonal abnormalities in cerebellar Purkinje cells of the Ts65Dn mouse,” Brain Research, vol. 1238, pp. 181–188, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. S. Lomoio, E. Scherini, and D. Necchi, “β-Amyloid overload does not directly correlate with SAPK/JNK activation and tau protein phosphorylation in the cerebellar cortex of Ts65Dn mice,” Brain Research, vol. 1297, pp. 198–206, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. Y. Chen, V. V. Dyakin, C. A. Branch et al., “In vivo MRI identifies cholinergic circuitry deficits in a Down syndrome model,” Neurobiology of Aging, vol. 30, no. 9, pp. 1453–1465, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. H. Seo and O. Isacson, “The hAPP-YAC transgenic model has elevated UPS activity in the frontal cortex similar to Alzheimer's disease and Down's syndrome,” Journal of Neurochemistry, vol. 114, no. 6, pp. 1819–1826, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. J. M. Delabar, R. Aflalo-Rattenbac, and N. Créau, “Developmental defects in trisomy 21 and mouse models,” TheScientificWorldJournal, vol. 6, pp. 1945–1964, 2006. View at Publisher · View at Google Scholar · View at Scopus
  90. I. T. Lott and M. Dierssen, “Cognitive deficits and associated neurological complications in individuals with Down's syndrome,” The Lancet Neurology, vol. 9, no. 6, pp. 623–633, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. K. Ishihara, K. Amano, E. Takaki et al., “Enlarged brain ventricles and impaired neurogenesis in the Ts1Cje and Ts2Cje mouse models of down syndrome,” Cerebral Cortex, vol. 20, no. 5, pp. 1131–1143, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. L. E. Olson, R. J. Roper, L. L. Baxter, E. J. Carlson, C. J. Epstein, and R. H. Reeves, “Down syndrome mouse models Ts65Dn, Ts1Cje, and Ms1Cje/Ts65Dn exhibit variable severity of cerebellar phenotypes,” Developmental Dynamics, vol. 230, no. 3, pp. 581–589, 2004. View at Publisher · View at Google Scholar · View at Scopus
  93. H. A. Lorenzi and R. H. Reeves, “Hippocampal hypocellularity in the Ts65Dn mouse originates early in development,” Brain Research, vol. 1104, no. 1, pp. 153–159, 2006. View at Publisher · View at Google Scholar · View at Scopus
  94. L. Chakrabarti, Z. Galdzicki, and T. F. Haydar, “Defects in embryonic neurogenesis and initial synapse formation in the forebrain of the Ts65Dn mouse model of Down syndrome,” Journal of Neuroscience, vol. 27, no. 43, pp. 11483–11495, 2007. View at Publisher · View at Google Scholar · View at Scopus
  95. L. Chakrabarti, T. K. Best, N. P. Cramer et al., “Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome,” Nature Neuroscience, vol. 13, no. 8, pp. 927–934, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. S. Guidi, E. Ciani, P. Bonasoni, D. Santini, and R. Bartesaghi, “Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with down syndrome,” Brain Pathology, vol. 21, no. 4, pp. 361–373, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. R. J. Roper, L. L. Baxter, N. G. Saran, D. K. Klinedinst, P. A. Beachy, and R. H. Reeves, “Defective cerebellar response to mitogenic Hedgehog signaling in Down's syndrome mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 5, pp. 1452–1456, 2006, Erratum in: Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 13, p. 5242, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. R. J. Roper, J. F. VanHorn, C. C. Cain, and R. H. Reeves, “A neural crest deficit in Down syndrome mice is associated with deficient mitotic response to Sonic hedgehog,” Mechanisms of Development, vol. 126, no. 3-4, pp. 212–219, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. R. C. von Rotz, B. M. Kohli, J. Bosset et al., “The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor,” Journal of Cell Science, vol. 117, no. 19, pp. 4435–4448, 2004. View at Publisher · View at Google Scholar · View at Scopus
  100. D. Satgé, A. J. Sasco, N. L. T. Carlsen et al., “A lack of neuroblastoma in Down syndrome: a study from 11 European countries,” Cancer Research, vol. 58, no. 3, pp. 448–452, 1998. View at Google Scholar · View at Scopus
  101. D. Satgé, D. Sommelet, A. Geneix, M. Nishi, P. Malet, and M. Vekemans, “A tumor profile in Down syndrome,” American Journal of Medical Genetics, vol. 78, no. 3, pp. 207–216, 1998. View at Publisher · View at Google Scholar
  102. D. Satgé and C. H. Rickert, “A medical enigma: persons with down syndrome do not develop medulloblastoma,” Neuroepidemiology, vol. 32, no. 2, p. 164, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. J. Park, Y. Oh, L. Yoo et al., “Dyrk1A phosphorylates p53 and inhibits proliferation of embryonic neuronal cells,” Journal of Biological Chemistry, vol. 285, no. 41, pp. 31895–31906, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. A. Contestabile, T. Fila, R. Bartesaghi, and E. Ciani, “Cell cycle elongation impairs proliferation of cerebellar granule cell precursors in the Ts65Dn mouse, an animal model for down syndrome,” Brain Pathology, vol. 19, no. 2, pp. 224–237, 2009. View at Publisher · View at Google Scholar · View at Scopus
  105. B. Hämmerle, E. Ulin, J. Guimera, W. Becker, F. Guillemot, and F. J. Tejedor, “Transient expression of Mnb/dyrk1a couples cell cycle exit and differentiation of neuronal precursors by inducing p27KIP1 expression and suppressing NOTCH signaling,” Development, vol. 138, no. 12, pp. 2543–2554, 2011. View at Publisher · View at Google Scholar · View at Scopus
  106. O. Ayrault, F. Zindy, J. Rehg, C. J. Sherr, and M. F. Roussel, “Two tumor suppressors, p27Kip1 and Patched-1, collaborate to prevent medulloblastoma,” Molecular Cancer Research, vol. 7, no. 1, pp. 33–40, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. O. Yabut, J. Domogauer, and G. D'Arcangelo, “Dyrk1A overexpression inhibits proliferation and induces premature neuronal differentiation of neural progenitor cells,” Journal of Neuroscience, vol. 30, no. 11, pp. 4004–4014, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. D. Satgé, N. Créau, R. Aflalo-Rattenbach, S. Ducassou, P. Lutz, and J. Bénard, “Down syndrome’s protection against neuroblastoma: the stromal and neural overmaturation tracks,” in Focus on Neuroblastoma Research, F. Columbus, Ed., chapter 3, pp. 57–100, Nova Science, New York, NY, USA, 2008. View at Google Scholar
  109. S. I. Harashima, Y. Wang, T. Horiuchi, Y. Seino, and N. Inagaki, “Purkinje cell protein 4 positively regulates neurite outgrowth and neurotransmitter release,” Journal of Neuroscience Research, vol. 89, no. 10, pp. 1519–1530, 2011. View at Publisher · View at Google Scholar · View at Scopus
  110. J. A. Golden and B. T. Hyman, “Development of the superior temporal neocortex is anomalous in trisomy 21,” Journal of Neuropathology and Experimental Neurology, vol. 53, no. 5, pp. 513–520, 1994. View at Google Scholar · View at Scopus
  111. N. Rueda, R. Mostany, A. Pazos, J. Flórez, and C. Martínez-Cué, “Cell proliferation is reduced in the dentate gyrus of aged but not young Ts65Dn mice, a model of Down syndrome,” Neuroscience Letters, vol. 380, no. 1-2, pp. 197–201, 2005. View at Publisher · View at Google Scholar · View at Scopus
  112. S. Clark, J. Schwalbe, M. R. Stasko, P. J. Yarowsky, and A. C. S. Costa, “Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome,” Experimental Neurology, vol. 200, no. 1, pp. 256–261, 2006. View at Publisher · View at Google Scholar · View at Scopus
  113. J. A. Troca-Marín, A. Alves-Sampaio, and M. L. Montesinos, “An increase in basal BDNF provokes hyperactivation of the Akt-Mammalian target of rapamycin pathway and deregulation of local dendritic translation in a mouse model of down's syndrome,” Journal of Neuroscience, vol. 31, no. 26, pp. 9445–9455, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. H. A. Bimonte-Nelson, C. L. Hunter, M. E. Nelson, and A. C. E. Granholm, “Frontal cortex BDNF levels correlate with working memory in an animal model of Down syndrome,” Behavioural Brain Research, vol. 139, no. 1-2, pp. 47–57, 2003. View at Publisher · View at Google Scholar · View at Scopus
  115. G. Dogliotti, E. Galliera, F. Licastro, and M. M. Corsi, “Age-related changes in plasma levels of BDNF in Down syndrome patients,” Immunity and Ageing, vol. 7, article 2, 2010. View at Publisher · View at Google Scholar · View at Scopus
  116. A. Alves-Sampaio, J. A. Troca-Marín, and M. L. Montesinos, “NMDA-Mediated regulation of DSCAM dendritic local translation is lost in a mouse model of Down's syndrome,” Journal of Neuroscience, vol. 30, no. 40, pp. 13537–13548, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. S. Bahn, M. Mimmack, M. Ryan et al., “Neuronal target genes of the neuron-restrictive silencer factor in neurospheres derived from fetuses with Down's syndrome: a gene expression study,” Lancet, vol. 359, no. 9303, pp. 310–315, 2002. View at Publisher · View at Google Scholar · View at Scopus
  118. C. Canzonetta, C. Mulligan, S. Deutsch et al., “DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome,” American Journal of Human Genetics, vol. 83, no. 3, pp. 388–400, 2008. View at Publisher · View at Google Scholar · View at Scopus
  119. S. Takashima, L. E. Becker, D. L. Armstrong, and F. W. Chan, “Abnormal neuronal development in the visual cortex of the human fetus and infant with Down's syndrome. A quantitative and qualitative Golgi study,” Brain Research, vol. 225, no. 1, pp. 1–21, 1981. View at Publisher · View at Google Scholar · View at Scopus
  120. L. E. Becker, D. L. Armstrong, and F. Chan, “Dendritic atrophy in children with Down's syndrome,” Annals of Neurology, vol. 20, no. 4, pp. 520–526, 1986. View at Google Scholar · View at Scopus
  121. M. Dierssen, R. Benavides-Piccione, C. Martínez-Cué et al., “Alterations of neocortical pyramidal cell phenotype in the Ts65Dn mouse model of Down syndrome: effects of environmental enrichment,” Cerebral Cortex, vol. 13, no. 7, pp. 758–764, 2003. View at Publisher · View at Google Scholar · View at Scopus
  122. A. M. Kleschevnikov, P. V. Belichenko, A. J. Villar, C. J. Epstein, R. C. Malenka, and W. C. Mobley, “Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of down syndrome,” Journal of Neuroscience, vol. 24, no. 37, pp. 8153–8160, 2004. View at Publisher · View at Google Scholar · View at Scopus
  123. F. Fernandez, W. Morishita, E. Zuniga et al., “Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome,” Nature Neuroscience, vol. 10, no. 4, pp. 411–413, 2007. View at Publisher · View at Google Scholar · View at Scopus
  124. P. V. Belichenko, E. Masliah, A. M. Kleschevnikov et al., “Synaptic structural abnormalities in the Ts65Dn mouse model of Down syndrome,” Journal of Comparative Neurology, vol. 480, no. 3, pp. 281–298, 2004. View at Publisher · View at Google Scholar · View at Scopus
  125. P. V. Belichenko, A. M. Kleschevnikov, E. Masliah et al., “Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of down syndrome,” Journal of Comparative Neurology, vol. 512, no. 4, pp. 453–466, 2009. View at Publisher · View at Google Scholar · View at Scopus
  126. A. M. Kleschevnikov, P. V. Belichenko, J. Gall et al., “Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome,” Neurobiology of Disease, vol. 45, no. 2, pp. 683–691, 2012. View at Publisher · View at Google Scholar
  127. M. Di Filippo, A. Tozzi, V. Ghiglieri et al., “Impaired plasticity at specific subset of striatal synapses in the Ts65Dn mouse model of Down syndrome,” Biological Psychiatry, vol. 67, no. 7, pp. 666–671, 2010. View at Publisher · View at Google Scholar · View at Scopus
  128. N. Rueda, M. Llorens-Martín, J. Flórez et al., “Memantine normalizes several phenotypic features in the Ts65Dn mouse model of down syndrome,” Journal of Alzheimer's Disease, vol. 21, no. 1, pp. 277–290, 2010. View at Publisher · View at Google Scholar · View at Scopus
  129. T. K. Best, R. J. Siarey, and Z. Galdzicki, “Ts65Dn, a mouse model of down syndrome, exhibits increased GABA B-induced potassium current,” Journal of Neurophysiology, vol. 97, no. 1, pp. 892–900, 2007. View at Publisher · View at Google Scholar · View at Scopus
  130. C. L. Maire, A. Wegener, C. Kerninon, and B. N. Oumesmar, “Gain-of-function of olig transcription factors enhances oligodendrogenesis and myelination,” Stem Cells, vol. 28, no. 9, pp. 1611–1622, 2010. View at Publisher · View at Google Scholar · View at Scopus
  131. A. Salehi, M. Faizi, D. Colas et al., “Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome,” Science Translational Medicine, vol. 1, no. 7, p. 7ra17, 2009. View at Publisher · View at Google Scholar · View at Scopus
  132. S. Hernández, J. Gilabert-Juan, J. M. Blasco-Ibáñez, C. Crespo, J. Nácher, and E. Varea, “Altered expression of neuropeptides in the primary somatosensory cortex of the Down syndrome model Ts65Dn,” Neuropeptides, vol. 46, no. 1, pp. 29–37, 2012. View at Publisher · View at Google Scholar
  133. F. Fernandez, J. C. Trinidad, M. Blank, D. D. Feng, A. L. Burlingame, and C. C. Garner, “Normal protein composition of synapses in Ts65Dn mice: a mouse model of Down syndrome,” Journal of Neurochemistry, vol. 110, no. 1, pp. 157–169, 2009. View at Publisher · View at Google Scholar · View at Scopus
  134. P. V. Belichenko, A. M. Kleschevnikov, A. Salehi, C. J. Epstein, and W. C. Mobley, “Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships,” Journal of Comparative Neurology, vol. 504, no. 4, pp. 329–345, 2007. View at Publisher · View at Google Scholar · View at Scopus
  135. P. V. Belichenko, A. M. Kleschevnikov, E. Masliah et al., “Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of down syndrome,” Journal of Comparative Neurology, vol. 512, no. 4, pp. 453–466, 2009. View at Publisher · View at Google Scholar · View at Scopus
  136. M. Ayberk Kurt, D. Ceri Davies, M. Kidd, M. Dierssen, and J. Flórez, “Synaptic deficit in the temporal cortex of partial trisomy 16 (Ts65Dn) mice,” Brain Research, vol. 858, no. 1, pp. 191–197, 2000. View at Publisher · View at Google Scholar · View at Scopus
  137. M. A. Kurt, M. I. Kafa, M. Dierssen, and D. C. Davies, “Deficits of neuronal density in CA1 and synaptic density in the dentate gyrus, CA3 and CA1, in a mouse model of Down syndrome,” Brain Research, vol. 1022, no. 1-2, pp. 101–109, 2004. View at Publisher · View at Google Scholar · View at Scopus
  138. N. P. Belichenko, P. V. Belichenko, A. M. Kleschevnikov, A. Salehi, R. H. Reeves, and W. C. Mobley, “The “Down syndrome critical region” is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome,” Journal of Neuroscience, vol. 29, no. 18, pp. 5938–5948, 2009. View at Publisher · View at Google Scholar · View at Scopus
  139. J. P. O'Bryan, “Intersecting pathways in cell biology,” Science Signaling, vol. 3, no. 152, article re10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  140. Y. Kim, J. Park, W. J. Song, and S. Chang, “Overexpression of Dyrk1A causes the defects in synaptic vesicle endocytosis,” NeuroSignals, vol. 18, no. 3, pp. 164–172, 2011. View at Publisher · View at Google Scholar · View at Scopus
  141. M. Mani, S. Y. Lee, L. Lucast et al., “The dual phosphatase activity of synaptojanin1 is required for both efficient synaptic vesicle endocytosis and reavailability at nerve terminals,” Neuron, vol. 56, no. 6, pp. 1004–1018, 2007. View at Publisher · View at Google Scholar · View at Scopus
  142. D. E. Berman, C. Dall'Armi, S. V. Voronov et al., “Oligomeric amyloid-β peptide disrupts phosphatidylinositol-4,5- bisphosphate metabolism,” Nature Neuroscience, vol. 11, no. 5, pp. 547–554, 2008. View at Publisher · View at Google Scholar · View at Scopus
  143. S. Guidi, P. Bonasoni, C. Ceccarelli et al., “Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome,” Brain Pathology, vol. 18, no. 2, pp. 180–197, 2008. View at Publisher · View at Google Scholar · View at Scopus
  144. G. Zdaniuk, T. Wierzba-Bobrowicz, G. M. Szpak, and T. Stȩpień, “Astroglia disturbances during development of the central nervous system in fetuses with Down's syndrome,” Folia Neuropathologica, vol. 49, no. 2, pp. 109–114, 2011. View at Google Scholar · View at Scopus
  145. R. X. Moldrich, L. Dauphinot, J. Laffaire et al., “Proliferation deficits and gene expression dysregulation in Down's syndrome (Ts1Cje) neural progenitor cells cultured from neurospheres,” Journal of Neuroscience Research, vol. 87, no. 14, pp. 3143–3152, 2009. View at Publisher · View at Google Scholar · View at Scopus
  146. F. Herrera, Q. Chen, W. H. Fischer, P. Maher, and D. R. Schubert, “Synaptojanin-1 plays a key role in astrogliogenesis: possible relevance for Down's syndrome,” Cell Death and Differentiation, vol. 16, no. 6, pp. 910–920, 2009. View at Publisher · View at Google Scholar · View at Scopus
  147. C. A. Hewitt, K. H. Ling, T. D. Merson et al., “Gene network disruptions and neurogenesis defects in the adult Ts1Cje mouse model of down syndrome,” PLoS ONE, vol. 5, no. 7, Article ID e11561, 2010. View at Publisher · View at Google Scholar · View at Scopus
  148. J. Lu, G. Esposito, C. Scuderi et al., “S100B and APP promote a gliocentric shift and impaired neurogenesis in down syndrome neural progenitors,” PLoS ONE, vol. 6, no. 7, Article ID e22126, 2011. View at Publisher · View at Google Scholar · View at Scopus
  149. A. Contestabile, T. Fila, C. Ceccarelli et al., “Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with down syndrome and in Ts65Dn mice,” Hippocampus, vol. 17, no. 8, pp. 665–678, 2007. View at Publisher · View at Google Scholar · View at Scopus
  150. A. W. Vorbrodt, S. Li, W. T. Brown, and N. Ramakrishna, “Increased expression of β-catenin in brain microvessels of a segmentally trisomic (Ts65Dn) mouse model of Down syndrome,” Brain Cell Biology, vol. 36, no. 5-6, pp. 203–211, 2008. View at Publisher · View at Google Scholar · View at Scopus
  151. N. Ramakrishna, H. C. Meeker, S. Li, W. T. Brown, R. Rao, and A. El Idrissi, “Upregulation of β-catenin expression in down syndrome model Ts65Dn mouse brain,” Neuroscience, vol. 161, no. 2, pp. 451–458, 2009. View at Publisher · View at Google Scholar · View at Scopus
  152. A. S. Karlsen and B. Pakkenberg, “Total numbers of neurons and glial cells in cortex and basal ganglia of aged brains with down syndrome-a stereological study,” Cerebral Cortex, vol. 21, no. 11, pp. 2519–2524, 2011. View at Publisher · View at Google Scholar
  153. J. A. Colombo, H. D. Reisin, M. Jones, and C. Bentham, “Development of interlaminar astroglial processes in the cerebral cortex of control and Down's syndrome human cases,” Experimental Neurology, vol. 193, no. 1, pp. 207–217, 2005. View at Publisher · View at Google Scholar · View at Scopus
  154. A. Rovelet-Lecrux, D. Hannequin, G. Raux et al., “APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy,” Nature Genetics, vol. 38, no. 1, pp. 24–26, 2006. View at Publisher · View at Google Scholar · View at Scopus
  155. J. Braudeau, B. Delatour, A. Duchon et al., “Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice,” Journal of Psychopharmacology, vol. 25, no. 8, pp. 1030–1042, 2011. View at Publisher · View at Google Scholar
  156. C. Martínez-Cué, C. Baamonde, M. Lumbreras et al., “Differential effects of environmental enrichment on behavior and learning of male and female Ts65Dn mice, a model for Down syndrome,” Behavioural Brain Research, vol. 134, no. 1-2, pp. 185–200, 2002. View at Publisher · View at Google Scholar · View at Scopus
  157. T. Begenisic, M. Spolidoro, C. Braschi et al., “Environmental enrichment decreases GABAergic inhibition and improves cognitive abilities, synaptic plasticity, and visual functions in a mouse model of Down syndrome,” Frontiers in Cellular Neuroscience. In press.
  158. Delabar, J. M. Guedj, F. Luilier et al., Program No. 402.6, PGT Improves Learning and Synaptic Plasticity Markers in Ts65Dn Mouse Model of Down Syndrome, Neuroscience Meeting Planner, Society for Neuroscience, Washington, DC, USA, 2010.